Aviva PLC boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 1,159.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,154,701 shares of the company's stock after buying an additional 1,063,043 shares during the quarter. Aviva PLC owned 0.06% of Kenvue worth $24,653,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of KVUE. Janus Henderson Group PLC raised its holdings in shares of Kenvue by 40.6% during the third quarter. Janus Henderson Group PLC now owns 219,576 shares of the company's stock valued at $5,080,000 after purchasing an additional 63,400 shares during the last quarter. Integrated Wealth Concepts LLC grew its position in Kenvue by 12.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 35,022 shares of the company's stock worth $810,000 after purchasing an additional 3,962 shares during the period. Quarry LP raised its stake in Kenvue by 311.3% during the 3rd quarter. Quarry LP now owns 3,241 shares of the company's stock valued at $75,000 after buying an additional 2,453 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Kenvue by 168.4% during the 3rd quarter. Quantinno Capital Management LP now owns 81,314 shares of the company's stock valued at $1,881,000 after buying an additional 51,016 shares during the period. Finally, Kovitz Investment Group Partners LLC boosted its stake in shares of Kenvue by 27.4% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 61,804 shares of the company's stock worth $1,430,000 after buying an additional 13,304 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
Kenvue Trading Up 0.7 %
NYSE KVUE traded up $0.15 on Friday, hitting $22.02. 3,163,632 shares of the stock were exchanged, compared to its average volume of 16,883,026. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The firm has a market capitalization of $42.09 billion, a P/E ratio of 41.52, a P/E/G ratio of 2.62 and a beta of 1.02. The stock has a fifty day moving average price of $22.62 and a two-hundred day moving average price of $22.41.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.72%. Kenvue's dividend payout ratio (DPR) is 154.72%.
Analyst Ratings Changes
Several research analysts have issued reports on the company. UBS Group dropped their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective on the stock. Citigroup reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Finally, Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and an average target price of $23.96.
Get Our Latest Report on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
